University of Vermont

The University of Vermont Cancer Center

trials_others.html

Other Clinical Trials

The University of Vermont Cancer Center has many trials focused on varied research areas.

Status: Active - Recruiting
Study Title:
Translational Studies of Muscle Atrophy/Dysfunction in Individuals with Cancer Cachexia
Purpose: Unplanned weight loss, muscle atrophy, and fatigue, also known as cancer cachexia, often accompany certain cancers such as head and neck, lung, pancreatic, or gastric cancer. Yet some individuals, such as individuals with breast cancer, receive chemotherapy but do not lose weight but experience fatigue. Studies in animals have shown that some cancers promote the loss of certain types of proteins (the building blocks of your muscles) in skeletal muscle. This research study is designed to determine whether similar changes in these proteins occur in skeletal muscle in humans receiving treatment for cancer. Data from individuals who have experienced weight loss and muscle atrophy (i.e. cachexia) will be compared to cancer patients who have not lost weight.
ClinicalTrials.gov Identifier: n/a
Primary/Site/Co Investigator: Kim L. Dittus, MD
Contact: xx
Information: Specific clinicaltrials.gov study link
Institution Number: M11-218, VCC 1104
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Purpose: Researchers want to find out if an Investigational drug called TH-302 can help patients with advanced soft tissue sarcoma when it is combined with doxorubicin. The purpose of this study is to gather information on the safety and effect on your cancer of TH-302 in combination with doxorubicin. The study will also look at how the drug is processed in the body.
ClinicalTrials.gov Identifier: NCT01440088
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Karen Lepuschenko (802) 656-9924
Information:
Institution Number: M12-225
Protocol Research Type: Industry
Status: Active - Recruiting
Study Title:
Alternating Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma:  A Phase II Study of Alternating Sunitinib and Temsirolimus 
Purpose: In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on agents directed at blocking tumor and vascular growth pathways. Sunitinib blocks the vascular endothelial growth factor receptor (VEGFr) and temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR). Both sunitinib and temsirolimus are FDA approved agents for mRCC. When agents like these are given together, the toxicity increases but they can be given safely, at full doses, sequentially. We hypothesize that alternating these agents will double the progression free survival (PFS) of the agents when given sequentially.
ClinicalTrials.gov Identifier: NCT01517243
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Deb McAdoo (802) 656-9113
Information: http://www.clinicaltrials.gov/ct2/show/NCT01517243?term=metastatic+renal+cell&recr=Open&rank=12
Institution Number: M13-004, DMS 1011 (in collaboration with Dartmouth Medical School)
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
Treatment Choices of Men with Good-Risk Prostate Cancer
Purpose: This study will involve men with good-risk prostate cancer and their clinicians. The study will occur in two phases. First, clinicians will be asked to complete a one-time interview regarding their experiences and clinical reasoning when treating men with good-risk prostate cancer (Aim 1). Also, approximately 40 men (10 of the 40 from UVM) will be asked to complete a one-time interview about their feelings and knowledge regarding their cancer diagnosis and treatment options and the things they considered when making a decision about treatment (Aim 1).
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Scott Perrapato, DO
Contact: Deb McAdoo (802) 656-9113
Information: N/A
Institution Number: M13-054, VCC 1214
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
Purpose: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.
ClinicalTrials.gov Identifier: NCT00430183
Primary/Site/Co Investigator: Steve Ades, MD
Contact: Deb McAdoo (802) 656-9113
Information: http://www.clinicaltrials.gov/ct2/show/record/NCT00430183?term=calgb+90203&rank=1
Institution Number: M95-106, CALGB 90203
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Automated Systems for Detection and Molecular Characterization of Circulating Tumor Cells
Purpose: Various types of cancer like breast cancer or prostate cancer frequently sends cancer cells to the bone marrow that can grow undetected and since undetected may go untreated. The purpose of this study is to develop an accurate method to detect the presence of cancer cells that have spread to the blood and bone marrow. In order to develop this test, the researchers need to study blood samples from individuals that have cancer. Specifically, the current protocol is aimed at developing an automated method to reliably detect and characterize the circulating tumor cells at a concentration below one in 106 – 107 normal white blood cells from whole blood. The assay will be tested in real clinical blood samples and their clinical sensitivity and specificity evaluated and compared against other methods.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: David Krag, MD
Contact: Eileen Caffry (802) 656-3447
Information: N/A
Institution Number: CHRMS M12-198
Protocol Research Type: Company Sponsored (Advanced Cell Diagnostics)
Status: Active - Recruiting
Study Title: Millennium C16014 / A Phase 3, Randomized, Double-blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma
Purpose: The purpose of this research study is to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with newly diagnosed multiple myeloma.
ClinicalTrials.gov Identifier: NCT01850524
Primary/Site/Co Investigator:
Contact: Karen Lepuschenko (802) 656-9924
Information: N/A
Institution Number: M14-016
Protocol Research Type: Industry Initiated
Status: Active - Recruiting
Study Title: A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Purpose: Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a hypomethylating agent (HMA) used to treat MDS. In this study, patients with intermediate- or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the safety of the study treatment. Safety assessments will include echocardiograms, electrocardiograms and routine safety laboratory studies (hematology and serum chemistry). In addition, clinical response to treatment will be monitored using bone marrow aspirates or biopsies, and other routine methods.
ClinicalTrials.gov Identifier: NCT02018926
Contact: Hannah Eldred, BS, CRC (802) 656-9441
Information: http://www.clinicaltrials.gov/ct2/show/NCT02018926?term=methylgene+MDS+mocetinostat&rank=1
Institution Number: CHRMS 14-082
Protocol Research Type: Industry Sponsored

Last modified December 05 2014 01:29 PM